Zai Lab Limited  (ZLAB)
Other Ticker:  
Price: $27.5000 $0.21 0.770%
Day's High: $28.025 Week Perf: -2.17 %
Day's Low: $ 26.57 30 Day Perf: 11.11 %
Volume (M): 509 52 Wk High: $ 49.81
Volume (M$): $ 14,006 52 Wk Avg: $31.36
Open: $27.23 52 Wk Low: $22.35

 Market Capitalization (Millions $) 26,641
 Shares Outstanding (Millions) 969
 Employees 656
 Revenues (TTM) (Millions $) 263
 Net Income (TTM) (Millions $) -301
 Cash Flow (TTM) (Millions $) -330
 Capital Exp. (TTM) (Millions $) 12

Zai Lab Limited
Zai Lab Limited (ZLAB) is a Chinese biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines for the treatment of oncology, autoimmune, and infectious diseases. The company was founded in 2014 by Dr. Samantha Du, an experienced pharmaceutical executive with a proven track record of successful drug development and commercialization.

Zai Lab has a broad pipeline of product candidates that target a range of diseases, including several late-stage clinical programs that are approaching commercialization. The company's lead product candidate is Zejula, a PARP inhibitor that is currently in Phase III clinical trials for the treatment of ovarian cancer. The company is also developing other oncology drugs, including novel kinase inhibitors and immuno-oncology therapies.

In addition to its oncology pipeline, Zai Lab has several product candidates in development for autoimmune diseases, such as atopic dermatitis and rheumatoid arthritis, as well as infectious diseases, such as COVID-19 and hepatitis B.

Zai Lab has a strong track record of partnership and collaboration with leading biopharmaceutical companies, including Sanofi, Bristol Myers Squibb, and GlaxoSmithKline. These partnerships have provided Zai Lab with access to key technologies and expertise, and have helped to accelerate the development of its product candidates.

The company aims to become a leading biopharmaceutical company in China, and has invested heavily in building a world-class research and development infrastructure. This includes state-of-the-art laboratories and manufacturing facilities, as well as a team of experienced scientists and researchers.

Zai Lab has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has a solid balance sheet, with over $1 billion in cash, cash equivalents, and short-term investments as of March 31, 202

In summary, Zai Lab Limited is a rapidly growing Chinese biopharmaceutical company with a portfolio of innovative product candidates in oncology, autoimmune diseases, and infectious diseases. The company has established strong partnerships with leading biopharmaceutical companies and has invested heavily in research and development infrastructure. With a strong financial position and a growing pipeline of product candidates, Zai Lab is well-positioned for continued success in the biopharmaceutical industry.

   Company Address: 4560 Jinke Road Shanghai 201210
   Company Phone Number: 6163 2588   Stock Exchange / Ticker: NASDAQ ZLAB
   ZLAB is expected to report next financial results on February 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.


Zai Lab Limited's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com